This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Investigating the role of Orexin Receptor Agonists in treating narcolepsy.
Ticker(s): ALKS, TAK, CNTAWho's the expert?
Institution: Stanford
- Clinical Associate Professor, Neurology & Neurological Sciences & Clinical Associate Professor, Psychiatry and Behavioral Sciences - Sleep Medicine at Stanford.
- Manages 40 patients with narcolepsy and has prescribed SUNOSI.
- Research interests involve biomarkers of disease progression in REM sleep behavior disorder, and mechanisms and treatment of Postural Tachycardia Syndrome and Post-Acute COVID Syndrome; special interest in Autonomic Disorders, Sleep Disorders, and the interaction between these conditions.
Interview GoalThis call will focus on the current standard of care for narcolepsy along with an analysis of multiple orexin receptor 2 (OX2R) being developed for the treatment of narcolepsy. The therapies of interest include TAK-861 (oveporexton), ALKS 2680, and ORX142.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
